Major Depressive Disorder
Conditions
Keywords
Drug therapy
Brief summary
The purpose of this study is to evaluate the efficacy of vortioxetine (5, 10, and 20 mg) versus placebo during the first 28 weeks of the 32-week double-blind treatment period in the prevention of relapse in participants with MDD who responded to acute treatment with vortioxetine 10 mg.
Detailed description
The drug being tested in this study is called vortioxetine. Vortioxetine is being tested for the prevention of relapse in adults with major depressive disorder (MDD) who respond to daily treatment with vortioxetine. This study will look at relapse rates of MDD in people who take vortioxetine. The study will enroll approximately 1100 participants. All participants will receive vortioxetine 10 mg open-label for the first 16 weeks of the study. Participants who meet the appropriate MDD response criteria from the Week 8 Visit through Week 16 Visit will be eligible for randomization into the double-blind treatment period. Participants will be randomly assigned (by chance, like flipping a coin) to one of the four treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need): * Vortioxetine 5 mg * Vortioxetine 10 mg * Vortioxetine 20 mg * Placebo (dummy inactive pill) - this is a capsule that looks like the study drug but has no active ingredient All participants will be asked to take one capsule at the same time each day throughout the study. This multi-center trial will be conducted in the United States. The overall time to participate in this study is up to 55 weeks. Participants will make 19 visits to the clinic, and will be contacted by telephone 4 weeks after last dose of study drug for a follow-up assessment.
Interventions
DRUGVortioxetine
Vortioxetine capsules
DRUGPlacebo
Vortioxetine placebo-matching capsules
Sponsors
Takeda
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements. 2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures. 3. Suffers from recurrent major depressive disorder (MDD) as the primary diagnosis according to Diagnostic & Statistical Manual of Mental Disorders, 4th Edition - Text Revision (DSM-IV-TR) criteria (classification code 296.3x), and the current episode is confirmed by the Mini International Neuropsychiatric Interview (MINI). 4. Reported duration of the current episode is ≥8 weeks and ≤18months. 5. Had at least 2 other major depressive episodes (MDEs) before the current episode. 6. Has a Montgomery-Åsberg Depression Rating Scale (MADRS) total score ≥26 at the Screening and Baseline I visits. 7. Is a man or woman aged 18 to 75 years, inclusive. 8. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to routinely use adequate contraception from signing of the informed consent throughout the duration of the study and for 30 days after the last dose.
Exclusion criteria
1. Has received any investigational compound within 30 days prior to screening or 5 half-lives prior to screening, whichever is longer. 2. Has previously or is currently participating in this study. 3. Has participated in 2 or more clinical studies in the year prior to screening, or has participated in a clinical trial for a psychiatric condition that is exclusionary per this protocol. 4. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress. 5. Has one or more of the following: 1. Any current psychiatric disorder which is the primary focus of treatment other than MDD as defined in the DSM-IV-TR, and assessed by the MINI. 2. Current or history of: manic or hypomanic episode, schizophrenia or any other psychotic disorder, including schizoaffective disorder, major depression with psychotic features, bipolar depression with psychotic features, obsessive compulsive disorder (OCD), mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR. 3. Current diagnosis or history of alcohol or other substance abuse or dependence (excluding nicotine or caffeine) as defined in the DSM-IV-TR that has not been in full and sustained remission for at least 3 months from the day of screening (Participant must also have negative urine drug screen at Screening and Baseline I.) 4. Presence or history of a clinically significant neurological disorder (including epilepsy) as determined by the investigator. 5. Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease, etc). 6. Any Axis II disorder as defined by DSM-IV-TR that might compromise the study. 6. The current depressive symptoms of the participant are considered by the investigator to have been resistant to 2 adequate antidepressant treatments of at least 6 weeks duration each. 7. Has a history of lack of response to previous adequate treatment with vortioxetine for any MDD episode with adequate treatment considered to be known dose of vortioxetine in the approved recommended dose range for at least 6 weeks duration. 8. Has received electroconvulsive therapy, vagal nerve stimulation, or repetitive transcranial magnetic stimulation within 6 months prior to Screening. 9. Has started receiving formal cognitive or behavioral therapy, systematic psychotherapy within 30 days from screening or plans to initiate such therapy during the study (supportive therapy, marital therapy and bereavement counseling are allowed). 10. Has a significant risk of suicide according to the investigator's clinical judgment or has a score ≥5 on item 10 (suicidal thoughts) of the MADRS or has made a suicide attempt in the previous 6 months. 11. Is required to take excluded medications or it is anticipated that the participant will require treatment with at least 1 of the disallowed concomitant medications during the study. 12. Has a clinically significant unstable illness, for example hepatic impairment or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, rheumatologic, immunologic, hematological, infectious, dermatological disorder or metabolic disturbance. Note: For the purposes of this protocol fibromyalgia, obstructive sleep apnea, chronic pain diagnosis, and morbid obesity (BMI of \> 40) are considered unstable due to the potential impact on assessment of the primary endpoint. 13. Has a known history of or currently has increased intraocular pressure or is at risk of acute narrow-angle glaucoma. 14. Has 1 or more laboratory value outside the normal range, based on the blood or urine samples taken at the Screening Visit, that are considered by the investigator to be clinically significant; or the participant has any of the following values at the Screening Visit: 1. A serum creatinine value \>1.5 times the upper limits of normal (ULN). 2. A serum total bilirubin value \>1.5 xULN. 3. A serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value \>2 xULN. 15. Has glycosylated hemoglobin (HbA1C) ≥7% at screening and no prior diagnosis of diabetes and/or treatment for diabetes. NOTE: Participants with known stable diabetes are not excluded. 16. Has a thyroid stimulating hormone (TSH) value outside the normal range at the Screening Visit that is deemed clinically significant by the investigator. NOTE: Free T4 will be checked if TSH is out of range. If free T4 is abnormal the participant will be excluded. 17. Has clinically significant abnormal vital signs as determined by the investigator. 18. Has an abnormal electrocardiogram (ECG) as determined by the central reader and confirmed as clinically significant by the investigator. 19. Is positive for Hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibodies, or has a history of human immunodeficiency virus (HIV) infection. 20. Has a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability or efficacy. 21. The participant, in the opinion of the investigator, is unlikely to comply with the clinical study protocol or is unsuitable for any reason. 22. Has a history of hypersensitivity or allergies to vortioxetine. 23. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period. 24. The participant is considered to be treatment resistant, eg, the participant has not responded to adequate monotherapy treatments of at least 6 weeks' duration, or has only responded to combination or augmentation therapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time From Randomization to Relapse of Major Depressive Disorder During the First 28 Weeks of the 32-Week Double-Blind Treatment Period | From date of double-blind randomization (Week 16) up to relapse or first 28 weeks of Double-blind Period which occurs first (Up to Week 44) | Relapse was defined as either 1) MADRS Score ≥22, 2) lack of efficacy as determined by the investigator or 3) other unsatisfactory treatment response judged by the investigator. Time to relapse was defined as date of relapse - date of randomization + 1 (where date of relapse is the date of last dose, or date of last contact if date of last dose is missing, for participant with a relapse). Participants without relapse were censored at date of withdrawal or date of Week 28 visit, whichever was earliest. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score ranges from 0 to 60. Higher scores indicate greater severity of symptoms. The inter-quartile range (IQR) was 25th percentile to 75th percentile. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Double-blind Baseline (BL) II and Double-blind Period: Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32 | MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score range from 0 to 60. Higher score indicates greater severity of symptoms. Baseline II is defined as the last non-missing observation prior to the first dose of double-blind study drug. Mixed model for repeated measures (MMRM) was used for analyses. |
| Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Double-blind Baseline (BL) II and Double-blind Period: Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32 | The CGI-S is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participant who have the same diagnosis. Considering total clinical experience, a participant was assessed on severity of mental illness on the following scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=extremely ill. Baseline II is defined as the last non-missing observation prior to the first dose of double-blind study drug. MMRM was used for analyses. |
| Clinical Global Impression Scale-Global Improvement Scale (CGI-I) Score | Week 32 | The CGI-I scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale where 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse. |
| Time From Randomization to Relapse of Major Depressive Disorder During the Entire 32-Week Double-Blind Treatment Period | From date of double-blind randomization (Week 16) up to relapse or 32 weeks of Double-blind Period which occurs first (Up to Week 44) | Relapse was defined as either 1) MADRS Score ≥22, 2) lack of efficacy as determined by the investigator or 3) other unsatisfactory treatment response judged by the investigator. Time to relapse was defined as date of relapse - date of randomization + 1 (where date of relapse is the date of last dose, or date of last contact if date of last dose is missing, for participant with a relapse). Participants without relapse were censored. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score ranges from 0 to 60. Higher scores indicate greater severity of symptoms. The IQR was 25th percentile to 75th percentile. |
Countries
United States
Participant flow
Recruitment details
Participants took part in the study at 74 investigative sites in the United States from 10 February 2015 to 25 April 2019.
Pre-assignment details
Participants with diagnosis of major depressive disorder (MDD) were enrolled to receive vortioxetine 10 mg in the Open-label Period for up to 16 weeks. Responders (defined below) were randomized in 1:1:1:1 ratio to receive vortioxetine 5 mg, 10 mg or 20 mg or placebo for up to 32 weeks in the Double-blind Period.
Participants by arm
| Arm | Count |
|---|---|
| Open-label: Vortioxetine 10 mg Vortioxetine 10 mg, capsules, orally, once, daily (QD) up to 8 weeks. Participants who achieved response (defined as a ≥50% reduction in Montgomery Asberg Depression Rating Scale (MADRS) total score from Baseline) continued to receive vortioxetine 10 mg, capsules, orally, QD for up to Week 16 (stabilization period) in the Open-label Period. | 1,106 |
| Total | 1,106 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 |
|---|---|---|---|---|---|---|
| Double-blind Period | Lost to Follow-up | 0 | 8 | 8 | 6 | 5 |
| Double-blind Period | Missing | 0 | 1 | 0 | 0 | 0 |
| Double-blind Period | Noncompliance with Study Drug | 0 | 1 | 2 | 2 | 3 |
| Double-blind Period | Pretreatment Event/Adverse Event | 0 | 4 | 3 | 2 | 9 |
| Double-blind Period | Reason not Specified | 0 | 3 | 3 | 2 | 1 |
| Double-blind Period | Relapse | 0 | 50 | 25 | 25 | 26 |
| Double-blind Period | Significant Protocol Deviation | 0 | 2 | 7 | 3 | 3 |
| Double-blind Period | Voluntary Withdrawal | 0 | 12 | 8 | 9 | 11 |
| Open-label Period | Did not Meet Randomization Criteria | 162 | 0 | 0 | 0 | 0 |
| Open-label Period | Lack of Efficacy | 116 | 0 | 0 | 0 | 0 |
| Open-label Period | Lost to Follow-up | 55 | 0 | 0 | 0 | 0 |
| Open-label Period | Noncompliance with Study Drug | 10 | 0 | 0 | 0 | 0 |
| Open-label Period | Pregnancy | 1 | 0 | 0 | 0 | 0 |
| Open-label Period | Pretreatment Event/Adverse Event | 63 | 0 | 0 | 0 | 0 |
| Open-label Period | Reason not Specified | 9 | 0 | 0 | 0 | 0 |
| Open-label Period | Significant Protocol Deviation | 19 | 0 | 0 | 0 | 0 |
| Open-label Period | Voluntary Withdrawal | 91 | 0 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | Open-label: Vortioxetine 10 mg |
|---|---|
| Age, Continuous | 44.3 years STANDARD_DEVIATION 13.69 |
| Alcohol Consumption Consumes 2 to 6 Times per Week | 159 Participants |
| Alcohol Consumption Consumes Daily | 11 Participants |
| Alcohol Consumption Consumes Once a Week | 167 Participants |
| Alcohol Consumption Consumes Once Monthly or Less Consumes Often | 286 Participants |
| Alcohol Consumption Participant has Never Consumed | 332 Participants |
| Alcohol Consumption Participant was an Ex-Drinker | 151 Participants |
| Body Mass Index (BMI) | 29.39 kg/m^2 STANDARD_DEVIATION 5.731 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 145 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 961 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Height | 167.7 cm STANDARD_DEVIATION 9.38 |
| Race (NIH/OMB) American Indian or Alaska Native | 7 Participants |
| Race (NIH/OMB) Asian | 19 Participants |
| Race (NIH/OMB) Black or African American | 258 Participants |
| Race (NIH/OMB) More than one race | 19 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 10 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 3 Participants |
| Race (NIH/OMB) White | 790 Participants |
| Region of Enrollment United States | 1106 Participants |
| Sex: Female, Male Female | 807 Participants |
| Sex: Female, Male Male | 299 Participants |
| Smoking Classification Participant has Never Smoked | 705 Participants |
| Smoking Classification Participant is a Current Smoker | 215 Participants |
| Smoking Classification Participant is an Ex-smoker | 186 Participants |
| Weight | 82.92 kg STANDARD_DEVIATION 18.695 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 1,106 | 0 / 151 | 0 / 140 | 1 / 145 | 0 / 144 |
| other Total, other adverse events | 417 / 1,106 | 16 / 151 | 30 / 140 | 27 / 145 | 32 / 144 |
| serious Total, serious adverse events | 9 / 1,106 | 1 / 151 | 3 / 140 | 4 / 145 | 0 / 144 |
Outcome results
Primary
Time From Randomization to Relapse of Major Depressive Disorder During the First 28 Weeks of the 32-Week Double-Blind Treatment Period
Relapse was defined as either 1) MADRS Score ≥22, 2) lack of efficacy as determined by the investigator or 3) other unsatisfactory treatment response judged by the investigator. Time to relapse was defined as date of relapse - date of randomization + 1 (where date of relapse is the date of last dose, or date of last contact if date of last dose is missing, for participant with a relapse). Participants without relapse were censored at date of withdrawal or date of Week 28 visit, whichever was earliest. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score ranges from 0 to 60. Higher scores indicate greater severity of symptoms. The inter-quartile range (IQR) was 25th percentile to 75th percentile.
Time frame: From date of double-blind randomization (Week 16) up to relapse or first 28 weeks of Double-blind Period which occurs first (Up to Week 44)
Population: Full Analysis Set (FAS) included all participants who were randomized in the double-blind period and received at least 1 dose of double-blind study drug.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Double-blind: Placebo | Time From Randomization to Relapse of Major Depressive Disorder During the First 28 Weeks of the 32-Week Double-Blind Treatment Period | NA weeks |
| Double-blind: Vortioxetine 5 mg | Time From Randomization to Relapse of Major Depressive Disorder During the First 28 Weeks of the 32-Week Double-Blind Treatment Period | NA weeks |
| Double-blind: Vortioxetine 10 mg | Time From Randomization to Relapse of Major Depressive Disorder During the First 28 Weeks of the 32-Week Double-Blind Treatment Period | NA weeks |
| Double-blind: Vortioxetine 20 mg | Time From Randomization to Relapse of Major Depressive Disorder During the First 28 Weeks of the 32-Week Double-Blind Treatment Period | NA weeks |
Comparison: Double-blind Vortioxetine 5mg Vs Double-blind Placebop-value: 0.00695% CI: [0.323, 0.828]Cox Proportional Hazards Model
Comparison: Double-blind Vortioxetine 10 mg Vs Double-blind Placebop-value: 0.00295% CI: [0.296, 0.767]Cox Proportional Hazards Model
Comparison: Double-blind Vortioxetine 20 mg Vs Double-blind Placebop-value: 0.00395% CI: [0.298, 0.782]Cox Proportional Hazards Model
Secondary
Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed
The CGI-S is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participant who have the same diagnosis. Considering total clinical experience, a participant was assessed on severity of mental illness on the following scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=extremely ill. Baseline II is defined as the last non-missing observation prior to the first dose of double-blind study drug. MMRM was used for analyses.
Time frame: Double-blind Baseline (BL) II and Double-blind Period: Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
Population: FAS included all participants who were randomized in the double-blind period and received at least 1 dose of double-blind study drug. Number analyzed is the number of participants with data available for analysis at the given time-point.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Double-blind: Placebo | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 12 | 0.74 scores on scale | Standard Error 0.092 |
| Double-blind: Placebo | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 8 | 0.68 scores on scale | Standard Error 0.091 |
| Double-blind: Placebo | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 4 | 0.61 scores on scale | Standard Error 0.075 |
| Double-blind: Placebo | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 24 | 0.60 scores on scale | Standard Error 0.103 |
| Double-blind: Placebo | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 16 | 0.62 scores on scale | Standard Error 0.094 |
| Double-blind: Placebo | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 28 | 0.45 scores on scale | Standard Error 0.101 |
| Double-blind: Placebo | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 32 | 0.59 scores on scale | Standard Error 0.108 |
| Double-blind: Placebo | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 2 | 0.35 scores on scale | Standard Error 0.065 |
| Double-blind: Placebo | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 20 | 0.61 scores on scale | Standard Error 0.094 |
| Double-blind: Vortioxetine 5 mg | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 4 | 0.32 scores on scale | Standard Error 0.078 |
| Double-blind: Vortioxetine 5 mg | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 28 | 0.33 scores on scale | Standard Error 0.094 |
| Double-blind: Vortioxetine 5 mg | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 2 | 0.32 scores on scale | Standard Error 0.069 |
| Double-blind: Vortioxetine 5 mg | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 8 | 0.38 scores on scale | Standard Error 0.092 |
| Double-blind: Vortioxetine 5 mg | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 12 | 0.46 scores on scale | Standard Error 0.091 |
| Double-blind: Vortioxetine 5 mg | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 16 | 0.50 scores on scale | Standard Error 0.091 |
| Double-blind: Vortioxetine 5 mg | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 20 | 0.40 scores on scale | Standard Error 0.089 |
| Double-blind: Vortioxetine 5 mg | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 24 | 0.45 scores on scale | Standard Error 0.098 |
| Double-blind: Vortioxetine 5 mg | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 32 | 0.41 scores on scale | Standard Error 0.101 |
| Double-blind: Vortioxetine 10 mg | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 2 | 0.26 scores on scale | Standard Error 0.067 |
| Double-blind: Vortioxetine 10 mg | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 12 | 0.24 scores on scale | Standard Error 0.089 |
| Double-blind: Vortioxetine 10 mg | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 16 | 0.25 scores on scale | Standard Error 0.088 |
| Double-blind: Vortioxetine 10 mg | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 20 | 0.17 scores on scale | Standard Error 0.086 |
| Double-blind: Vortioxetine 10 mg | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 32 | 0.26 scores on scale | Standard Error 0.097 |
| Double-blind: Vortioxetine 10 mg | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 24 | 0.24 scores on scale | Standard Error 0.094 |
| Double-blind: Vortioxetine 10 mg | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 4 | 0.30 scores on scale | Standard Error 0.076 |
| Double-blind: Vortioxetine 10 mg | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 28 | 0.30 scores on scale | Standard Error 0.09 |
| Double-blind: Vortioxetine 10 mg | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 8 | 0.29 scores on scale | Standard Error 0.089 |
| Double-blind: Vortioxetine 20 mg | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 8 | 0.30 scores on scale | Standard Error 0.093 |
| Double-blind: Vortioxetine 20 mg | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 28 | 0.34 scores on scale | Standard Error 0.093 |
| Double-blind: Vortioxetine 20 mg | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 4 | 0.25 scores on scale | Standard Error 0.078 |
| Double-blind: Vortioxetine 20 mg | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 24 | 0.37 scores on scale | Standard Error 0.097 |
| Double-blind: Vortioxetine 20 mg | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 12 | 0.35 scores on scale | Standard Error 0.092 |
| Double-blind: Vortioxetine 20 mg | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 2 | 0.27 scores on scale | Standard Error 0.068 |
| Double-blind: Vortioxetine 20 mg | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 16 | 0.34 scores on scale | Standard Error 0.091 |
| Double-blind: Vortioxetine 20 mg | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 20 | 0.28 scores on scale | Standard Error 0.089 |
| Double-blind: Vortioxetine 20 mg | Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed | Change From BL II at Week 32 | 0.22 scores on scale | Standard Error 0.1 |
Comparison: Change From Baseline II at Week 2p-value: 0.73295% CI: [-0.2, 0.14]MMRM
Comparison: Change From Baseline II at Week 2p-value: 0.27395% CI: [-0.26, 0.07]MMRM
Comparison: Change From Baseline II at Week 2p-value: 0.36195% CI: [-0.24, 0.09]MMRM
Comparison: Change From Baseline II at Week 4p-value: 0.00495% CI: [-0.48, -0.09]MMRM
Comparison: Change From Baseline II at Week 4p-value: 0.00295% CI: [-0.5, -0.12]Least Squares Mean Difference
Comparison: Change From Baseline II at Week 4p-value: <0.00195% CI: [-0.55, -0.16]MMRM
Comparison: Change From Baseline II at Week 8p-value: 0.01495% CI: [-0.54, -0.06]MMRM
Comparison: Change From Baseline II at Week 8p-value: 0.00195% CI: [-0.63, -0.16]MMRM
Comparison: Change From Baseline II at Week 8p-value: 0.00295% CI: [-0.62, -0.14]MMRM
Comparison: Change From Baseline II at Week 12p-value: 0.02595% CI: [-0.51, -0.03]Least Squares Mean Difference
Comparison: Change From Baseline II at Week 12p-value: <0.00195% CI: [-0.74, -0.26]MMRM
Comparison: Change From Baseline II at Week 12p-value: 0.00295% CI: [-0.63, -0.15]MMRM
Comparison: Change From Baseline II at Week 16p-value: 0.33395% CI: [-0.36, 0.12]MMRM
Comparison: Change From Baseline II at Week 16p-value: 0.00295% CI: [-0.61, -0.13]MMRM
Comparison: Change From Baseline II at Week 16p-value: 0.02395% CI: [-0.53, -0.04]MMRM
Comparison: Change From Baseline II at Week 20p-value: 0.09295% CI: [-0.44, 0.03]MMRM
Comparison: Change From Baseline II at Week 20p-value: <0.00195% CI: [-0.67, -0.2]MMRM
Comparison: Change From Baseline II at Week 20p-value: 0.00895% CI: [-0.57, -0.09]MMRM
Comparison: Change From Baseline II at Week 24p-value: 0.24895% CI: [-0.42, 0.11]MMRM
Comparison: Change From Baseline II at Week 24p-value: 0.00695% CI: [-0.63, -0.1]MMRM
Comparison: Change From Baseline II at Week 24p-value: 0.08795% CI: [-0.5, 0.03]MMRM
Comparison: Change From Baseline II at Week 28p-value: 0.36295% CI: [-0.38, 0.14]MMRM
Comparison: Change From Baseline II at Week 28p-value: 0.25195% CI: [-0.4, 0.1]MMRM
Comparison: Change From Baseline II at Week 28p-value: 0.39195% CI: [-0.37, 0.14]MMRM
Comparison: Change From Baseline II at Week 32p-value: 0.20995% CI: [-0.45, 0.1]MMRM
Comparison: Change From Baseline II at Week 32p-value: 0.01895% CI: [-0.6, -0.06]MMRM
Comparison: Change From Baseline II at Week 32p-value: 0.00995% CI: [-0.65, -0.09]MMRM
Secondary
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score range from 0 to 60. Higher score indicates greater severity of symptoms. Baseline II is defined as the last non-missing observation prior to the first dose of double-blind study drug. Mixed model for repeated measures (MMRM) was used for analyses.
Time frame: Double-blind Baseline (BL) II and Double-blind Period: Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
Population: FAS included all participants who were randomized in the double-blind period and received at least 1 dose of double-blind study drug. Number analyzed is the number of participants with data available for analysis at the given time-point.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Double-blind: Placebo | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 2 | 2.70 scores on scale | Standard Error 0.461 |
| Double-blind: Placebo | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 16 | 5.77 scores on scale | Standard Error 0.724 |
| Double-blind: Placebo | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 24 | 5.69 scores on scale | Standard Error 0.765 |
| Double-blind: Placebo | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 20 | 5.95 scores on scale | Standard Error 0.699 |
| Double-blind: Placebo | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 12 | 6.43 scores on scale | Standard Error 0.704 |
| Double-blind: Placebo | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 4 | 4.99 scores on scale | Standard Error 0.576 |
| Double-blind: Placebo | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 32 | 6.55 scores on scale | Standard Error 0.858 |
| Double-blind: Placebo | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 28 | 5.07 scores on scale | Standard Error 0.774 |
| Double-blind: Placebo | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 8 | 5.98 scores on scale | Standard Error 0.688 |
| Double-blind: Vortioxetine 5 mg | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 32 | 3.46 scores on scale | Standard Error 0.815 |
| Double-blind: Vortioxetine 5 mg | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 24 | 3.78 scores on scale | Standard Error 0.733 |
| Double-blind: Vortioxetine 5 mg | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 20 | 3.34 scores on scale | Standard Error 0.673 |
| Double-blind: Vortioxetine 5 mg | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 12 | 3.51 scores on scale | Standard Error 0.701 |
| Double-blind: Vortioxetine 5 mg | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 2 | 2.23 scores on scale | Standard Error 0.49 |
| Double-blind: Vortioxetine 5 mg | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 16 | 3.73 scores on scale | Standard Error 0.707 |
| Double-blind: Vortioxetine 5 mg | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 4 | 2.56 scores on scale | Standard Error 0.599 |
| Double-blind: Vortioxetine 5 mg | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 28 | 3.18 scores on scale | Standard Error 0.73 |
| Double-blind: Vortioxetine 5 mg | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 8 | 3.03 scores on scale | Standard Error 0.698 |
| Double-blind: Vortioxetine 10 mg | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 8 | 2.14 scores on scale | Standard Error 0.679 |
| Double-blind: Vortioxetine 10 mg | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 12 | 1.92 scores on scale | Standard Error 0.684 |
| Double-blind: Vortioxetine 10 mg | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 20 | 1.86 scores on scale | Standard Error 0.653 |
| Double-blind: Vortioxetine 10 mg | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 24 | 2.19 scores on scale | Standard Error 0.707 |
| Double-blind: Vortioxetine 10 mg | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 28 | 2.72 scores on scale | Standard Error 0.699 |
| Double-blind: Vortioxetine 10 mg | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 2 | 1.47 scores on scale | Standard Error 0.471 |
| Double-blind: Vortioxetine 10 mg | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 4 | 1.98 scores on scale | Standard Error 0.581 |
| Double-blind: Vortioxetine 10 mg | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 16 | 2.08 scores on scale | Standard Error 0.688 |
| Double-blind: Vortioxetine 10 mg | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 32 | 2.58 scores on scale | Standard Error 0.784 |
| Double-blind: Vortioxetine 20 mg | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 8 | 2.97 scores on scale | Standard Error 0.708 |
| Double-blind: Vortioxetine 20 mg | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 24 | 3.16 scores on scale | Standard Error 0.73 |
| Double-blind: Vortioxetine 20 mg | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 4 | 2.48 scores on scale | Standard Error 0.602 |
| Double-blind: Vortioxetine 20 mg | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 2 | 2.29 scores on scale | Standard Error 0.481 |
| Double-blind: Vortioxetine 20 mg | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 28 | 3.20 scores on scale | Standard Error 0.726 |
| Double-blind: Vortioxetine 20 mg | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 20 | 3.18 scores on scale | Standard Error 0.675 |
| Double-blind: Vortioxetine 20 mg | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 12 | 2.79 scores on scale | Standard Error 0.707 |
| Double-blind: Vortioxetine 20 mg | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 32 | 2.97 scores on scale | Standard Error 0.815 |
| Double-blind: Vortioxetine 20 mg | Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Change From BL II at Week 16 | 3.14 scores on scale | Standard Error 0.712 |
Comparison: Change From Baseline II at Week 2p-value: 0.48895% CI: [-1.57, 0.75]MMRM
Comparison: Change From Baseline II at Week 4p-value: 0.00295% CI: [-3.93, -0.93]MMRM
Comparison: Change From Baseline II at Week 2p-value: 0.42195% CI: [-1.63, 0.68]MMRM
Comparison: Change From Baseline II at Week 2p-value: 0.03795% CI: [-2.39, -0.08]MMRM
Comparison: Change From Baseline II at Week 4p-value: <0.00195% CI: [-4.49, -1.51]MMRM
Comparison: Change From Baseline II at Week 4p-value: 0.00195% CI: [-4.02, -0.98]MMRM
Comparison: Change From Baseline II at Week 8p-value: 0.00195% CI: [-4.76, -1.13]MMRM
Comparison: Change From Baseline II at Week 8p-value: <0.00195% CI: [-5.64, -2.03]MMRM
Comparison: Change From Baseline II at Week 8p-value: 0.00195% CI: [-4.84, -1.16]MMRM
Comparison: Change From Baseline II at Week 12p-value: 0.00295% CI: [-4.76, -1.08]MMRM
Comparison: Change From Baseline II at Week 12p-value: <0.00195% CI: [-6.34, -2.68]MMRM
Comparison: Change From Baseline II at Week 12p-value: <0.00195% CI: [-5.5, -1.78]MMRM
Comparison: Change From Baseline II at Week 16p-value: 0.03395% CI: [-3.92, -0.16]MMRM
Comparison: Change From Baseline II at Week 16p-value: <0.00195% CI: [-5.55, -1.82]MMRM
Comparison: Change From Baseline II at Week 16p-value: 0.00795% CI: [-4.52, -0.73]MMRM
Comparison: Change From Baseline II at Week 20p-value: 0.00495% CI: [-4.4, -0.82]MMRM
Comparison: Change From Baseline II at Week 20p-value: <0.00195% CI: [-5.86, -2.31]MMRM
Comparison: Change From Baseline II at Week 20p-value: 0.00395% CI: [-4.57, -0.96]MMRM
Comparison: Change From Baseline II at Week 24p-value: 0.05795% CI: [-3.89, 0.06]MMRM
Comparison: Change From Baseline II at Week 24p-value: <0.00195% CI: [-5.46, -1.55]MMRM
Comparison: Change From Baseline II at Week 24p-value: 0.01295% CI: [-4.51, -0.55]MMRM
Comparison: Change From Baseline II at Week 28p-value: 0.06195% CI: [-3.88, 0.09]MMRM
Comparison: Change From Baseline II at Week 28p-value: 0.01895% CI: [-4.31, -0.4]MMRM
Comparison: Change From Baseline II at Week 28p-value: 0.06595% CI: [-3.87, 0.12]MMRM
Comparison: Change From Baseline II at Week 32p-value: 0.00795% CI: [-5.31, -0.86]MMRM
Comparison: Change From Baseline II at Week 32p-value: <0.00195% CI: [-6.16, -1.77]MMRM
Comparison: Change From Baseline II at Week 32p-value: 0.00295% CI: [-5.82, -1.34]MMRM
Secondary
Clinical Global Impression Scale-Global Improvement Scale (CGI-I) Score
The CGI-I scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale where 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse.
Time frame: Week 32
Population: FAS included all participants who were randomized in the double-blind period and received at least 1 dose of double-blind study drug. Overall number of participants analyzed is the number of participants with data available for analyses.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Double-blind: Placebo | Clinical Global Impression Scale-Global Improvement Scale (CGI-I) Score | 4.4 scores on scale | Standard Deviation 1.47 |
| Double-blind: Vortioxetine 5 mg | Clinical Global Impression Scale-Global Improvement Scale (CGI-I) Score | 3.9 scores on scale | Standard Deviation 1.51 |
| Double-blind: Vortioxetine 10 mg | Clinical Global Impression Scale-Global Improvement Scale (CGI-I) Score | 3.5 scores on scale | Standard Deviation 1.72 |
| Double-blind: Vortioxetine 20 mg | Clinical Global Impression Scale-Global Improvement Scale (CGI-I) Score | 3.7 scores on scale | Standard Deviation 1.56 |
Secondary
Time From Randomization to Relapse of Major Depressive Disorder During the Entire 32-Week Double-Blind Treatment Period
Relapse was defined as either 1) MADRS Score ≥22, 2) lack of efficacy as determined by the investigator or 3) other unsatisfactory treatment response judged by the investigator. Time to relapse was defined as date of relapse - date of randomization + 1 (where date of relapse is the date of last dose, or date of last contact if date of last dose is missing, for participant with a relapse). Participants without relapse were censored. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score ranges from 0 to 60. Higher scores indicate greater severity of symptoms. The IQR was 25th percentile to 75th percentile.
Time frame: From date of double-blind randomization (Week 16) up to relapse or 32 weeks of Double-blind Period which occurs first (Up to Week 44)
Population: FAS included all participants who were randomized in the double-blind period and received at least 1 dose of double-blind study drug.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Double-blind: Placebo | Time From Randomization to Relapse of Major Depressive Disorder During the Entire 32-Week Double-Blind Treatment Period | NA weeks |
| Double-blind: Vortioxetine 5 mg | Time From Randomization to Relapse of Major Depressive Disorder During the Entire 32-Week Double-Blind Treatment Period | NA weeks |
| Double-blind: Vortioxetine 10 mg | Time From Randomization to Relapse of Major Depressive Disorder During the Entire 32-Week Double-Blind Treatment Period | NA weeks |
| Double-blind: Vortioxetine 20 mg | Time From Randomization to Relapse of Major Depressive Disorder During the Entire 32-Week Double-Blind Treatment Period | NA weeks |
Comparison: Double-blind Vortioxetine 5mg Vs Double-blind Placebop-value: 0.00295% CI: [0.302, 0.766]Cox Proportional Hazards Model
Comparison: Double-blind Vortioxetine 10 mg Vs Double-blind Placebop-value: <0.00195% CI: [0.286, 0.725]Cox Proportional Hazards Model
Comparison: Double-blind Vortioxetine 20 mg Vs Double-blind Placebop-value: 0.00295% CI: [0.304, 0.771]Cox Proportional Hazards Model